T cell activation—the process by which these key immune defenders recognize threats and mobilize against them—depends on ...

For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...

Engineers at the University of Pennsylvania have developed a new type of lipid nanoparticle (LNP) that could one day serve as ...

Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer in mice—effectively ...

Researchers at the Kennedy Institute of Rheumatology have found that physically resisting the formation of an immunological synapse actually promotes a stronger immune response. The findings could ...

Chimeric antigen receptor (CAR) T cell-based therapy has greatly improved cancer treatment, especially for hematologic cancers. 1 By providing T cells with synthetic receptors that target tumor ...

CAR architecture has evolved through four generations. The first relied solely on CD3ζ and lacked potency. Second-generation receptors added either CD28 or 4-1BB costimulation, striking a balance ...

Researchers at the Keck School of Medicine of University of Southern California (USC) have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response ...

A tumor “don’t‑eat‑me” shield also hides pro‑immune danger signals; new antibodies that unmask this hidden cue could make cancers more vulnerable to immune attack.